AU2017213844A1 - Anti-ROR1 antibodies and uses thereof - Google Patents

Anti-ROR1 antibodies and uses thereof Download PDF

Info

Publication number
AU2017213844A1
AU2017213844A1 AU2017213844A AU2017213844A AU2017213844A1 AU 2017213844 A1 AU2017213844 A1 AU 2017213844A1 AU 2017213844 A AU2017213844 A AU 2017213844A AU 2017213844 A AU2017213844 A AU 2017213844A AU 2017213844 A1 AU2017213844 A1 AU 2017213844A1
Authority
AU
Australia
Prior art keywords
ser
leu
gly
pro
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017213844A
Other languages
English (en)
Inventor
Ashwini BALAKRISHNAN
Benjamin G. Hoffstrom
Julie RANDOLPH-HABECKER
Stanley R. Riddell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of AU2017213844A1 publication Critical patent/AU2017213844A1/en
Assigned to FRED HUTCHINSON CANCER CENTER reassignment FRED HUTCHINSON CANCER CENTER Request for Assignment Assignors: FRED HUTCHINSON CANCER RESEARCH CENTER
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017213844A 2016-02-02 2017-02-02 Anti-ROR1 antibodies and uses thereof Abandoned AU2017213844A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662290337P 2016-02-02 2016-02-02
US62/290,337 2016-02-02
US201662324876P 2016-04-19 2016-04-19
US62/324,876 2016-04-19
PCT/US2017/016300 WO2017136607A1 (en) 2016-02-02 2017-02-02 Anti-ror1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2017213844A1 true AU2017213844A1 (en) 2018-08-02

Family

ID=58054529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017213844A Abandoned AU2017213844A1 (en) 2016-02-02 2017-02-02 Anti-ROR1 antibodies and uses thereof

Country Status (9)

Country Link
US (3) US10968275B2 (enExample)
EP (2) EP3411408B1 (enExample)
JP (2) JP7029401B2 (enExample)
CN (1) CN108699149B (enExample)
AU (1) AU2017213844A1 (enExample)
CA (1) CA3012827A1 (enExample)
ES (1) ES2903228T3 (enExample)
MX (1) MX2018009011A (enExample)
WO (1) WO2017136607A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009254A (es) 2015-01-16 2017-10-12 Juno Therapeutics Inc Anticuerpos y receptores de antigeno quimerico especificos para ror1.
HK1254836A1 (zh) 2015-10-30 2019-07-26 Nbe-Therapeutics Ag 抗-ror1抗体
RU2766190C2 (ru) 2016-01-20 2022-02-09 Дзе Скриппс Рисерч Инститьют Композиции антител к ror1 и соответствующие способы
EP3411408B1 (en) 2016-02-02 2021-12-08 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
CA3080395A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
EP3936523A4 (en) * 2019-01-08 2022-09-07 Shenzhen University ANTIBODY DETECTION OF MALIGNANT TUMOR CELLS AND THEIR APPLICATIONS
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
WO2023186100A1 (zh) * 2022-04-02 2023-10-05 山东先声生物制药有限公司 抗ror1的抗体及其用途
EP4563597A1 (en) * 2022-07-26 2025-06-04 Aimed Bio Inc. Anti-ror1 antibody and use thereof
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN120476147A (zh) * 2022-12-27 2025-08-12 上海医药集团生物治疗技术有限公司 靶向ror1的抗原结合蛋白
CN115894691A (zh) * 2022-12-27 2023-04-04 上海医药集团生物治疗技术有限公司 靶向ror1的抗原结合蛋白
CN116183472B (zh) * 2023-04-25 2023-08-18 上海益诺思生物技术股份有限公司 Cba法检测非人类灵长类动物细胞因子的验证方法
WO2025007910A1 (en) * 2023-07-04 2025-01-09 TJ Biopharma (Shanghai) Co., Ltd. Anti-ror1 antibodies and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA114536A (en) 1908-09-18 1908-10-13 Adolphe Chalas Nickel recovering process
CA138293A (en) 1911-11-06 1912-02-06 Charles E. Archie Variable speed gearing
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
KR20060088905A (ko) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
WO2003085093A2 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
EP2229955A1 (en) 2003-10-16 2010-09-22 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment using the same
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
MX2011000117A (es) * 2008-07-10 2011-02-25 Toray Industries Composicion farmaceutica para tratamiento y prevencion de cancer.
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CA2759733C (en) 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
NZ743310A (en) 2011-03-23 2022-11-25 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
EP2741770A4 (en) 2011-08-09 2014-12-31 Athera Biotechnologies Ab ANTIBODY BINDING TO PHOSPHORYLCHOLIN (PC) AND / OR PC CONJUGATES
SG11201400859SA (en) 2011-09-22 2014-04-28 Amgen Inc Cd27l antigen binding proteins
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
WO2014164554A1 (en) 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells
ES2715413T3 (es) 2014-07-29 2019-06-04 Cellectis Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer
BR112017008710A8 (pt) 2014-10-27 2023-04-25 Hutchinson Fred Cancer Res Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
MX2017009254A (es) 2015-01-16 2017-10-12 Juno Therapeutics Inc Anticuerpos y receptores de antigeno quimerico especificos para ror1.
EP3298032A1 (en) 2015-05-18 2018-03-28 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
EP3411408B1 (en) 2016-02-02 2021-12-08 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive

Also Published As

Publication number Publication date
US10968275B2 (en) 2021-04-06
US20210147540A1 (en) 2021-05-20
MX2018009011A (es) 2018-11-19
JP2022028918A (ja) 2022-02-16
JP2019511904A (ja) 2019-05-09
CN108699149B (zh) 2023-01-06
EP3411408A1 (en) 2018-12-12
WO2017136607A1 (en) 2017-08-10
US20240352119A1 (en) 2024-10-24
US20190040132A1 (en) 2019-02-07
EP3411408B1 (en) 2021-12-08
EP4006056A1 (en) 2022-06-01
CN108699149A (zh) 2018-10-23
JP7029401B2 (ja) 2022-03-03
ES2903228T3 (es) 2022-03-31
US11932691B2 (en) 2024-03-19
CA3012827A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
US20240352119A1 (en) Anti-ror1 antibodies and uses thereof
AU2013301341B2 (en) Anti-tumour response to modified self-epitopes
KR102056137B1 (ko) 암의 검출 방법
CN118955712A (zh) Cldn 18.2特异性单克隆抗体及其使用方法
DK2876446T3 (en) Method for detecting cancer
TW201922784A (zh) ４﹘１ｂｂ抗體及其製備方法和應用
CA2960466C (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
EP4269436A1 (en) Claudin18.2 chimeric antigen receptor and use thereof
CA2842513A1 (en) Novel anti - cxcr4 antibody and its use for the detection and diagnosis of cancer
EP3239176B1 (en) Anti-active gip antibody
US20240166752A1 (en) Antibody and use thereof
HK40075786A (en) Anti-ror1 antibodies and uses thereof
TW201840588A (zh) 抗ｇｐｒ２０抗體
HK40000385B (en) Anti-ror1 antibodies and uses thereof
KR20210122813A (ko) 항체 및 그의 기능성 단편
WO2025189420A1 (en) Chimeric antigen receptor against programmed deathligand 1 (pd-l1) and application thereof
CN121008043A (zh) Axl-gas6复合物的检测方法及在心肌梗死患者中的应用
JPWO2018034259A1 (ja) Ｔｍｅｍ１３２ａに結合する抗体、抗がん剤、およびがんの検査方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: FRED HUTCHINSON CANCER CENTER

Free format text: FORMER APPLICANT(S): FRED HUTCHINSON CANCER RESEARCH CENTER

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application